-
Product Insights
NewNet Present Value Model: Concert Pharmaceuticals Inc’s Deuruxolitinib Phosphate
Empower your strategies with our Net Present Value Model: Concert Pharmaceuticals Inc's Deuruxolitinib Phosphate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Alopecia Areata – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia Areata - Drugs In Development, 2023’, provides an overview of the Alopecia Areata pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia Areata, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia - Drugs In Development, 2023’, provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Track & Monitor
Innovation in pharma: deuterated drug synthesis
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s deuterated drug synthesis segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ozuriftamab Vedotin in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ozuriftamab Vedotin in Oropharyngeal Cancer Drug Details: BA-3021 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Deuruxolitinib Phosphate in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deuruxolitinib Phosphate in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deuruxolitinib Phosphate in Alopecia Areata Drug Details: Deuruxolitinib phosphate (CTP-543, Deuterated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Farletuzumab Ecteribulin in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Farletuzumab Ecteribulin in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Farletuzumab Ecteribulin in Peritoneal Cancer Drug Details: Farletuzumab ecteribulin (MORAb-202)...
-
Thematic Analysis
Metaverse in Media – Thematic Intelligence
Metaverse in Media Market Analysis Report Overview The metaverse is a virtual world where users share experiences and interact in real-time within simulated scenarios. The metaverse brings together a range of next-generation technologies, from cloud computing to artificial intelligence (AI), blockchain, cryptocurrencies, augmented reality (AR), virtual reality (VR), and digital twins. The companies in the media sector investing in the metaverse are mainly concentrating their efforts on creating virtual worlds and organizing immersive experiences within them. These virtual worlds also...
-
Company Profile
Mizuno Corp – Company Profile
Mizuno Corp (Mizuno) is a manufactures and distributes of sportswear, sporting equipment, and footwear. The company's product portfolio includes baseball equipment, sportswear, footwear, apparel, golf, and skiing equipment. The company provides equipment for baseball, golf, volleyball, rugby, table tennis, running. It is actively involved in managing national facilities, deploying school businesses, and constructing sports facilities under concerted efforts with the government. The company has business operations across Europe, Asia, Oceania, North America, Latin America, the Middle East and Africa. Mizuno...
Add to Basket -
Company Profile
Concert Pharmaceuticals Inc – Company Profile
Concert Pharmaceuticals Inc (Concert Pharma) is a late-stage clinical biotechnology company. It discovers and develops drugs for impacted patient care and addresses medical needs. The company develops its products using its deuterated chemical entity (DCE) platform for the treatment of autoimmune dermatological conditions, which includes alopecia areata. The alopecia areata occurs when the immune system attacks the hair follicles and is characterized as non-scarring hair loss. It also develops CTP-543, which is an oral inhibitor of Janus kinases JAK1 and...
Add to Basket